A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...
The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...
The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity for weight loss, doctors are observing a ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil ...
Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health conditions.
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...